403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
World Disability Day: AbbVie supports key Jeddah event
(MENAFN- Arab News) In recognition of the annual World Disability Day AbbVie aleadingglobal biopharmaceutical company supported the Disabled Children's Association event in Jeddah.
The event included a number of activities and programs for children under the theme of 'Sustainable Development the promise of technology.'
It was held with the support of Prince Sultan bin Naser bin Abdulaziz.
AbbVie's support for such programs aims to highlight the strong potential of the children with disabilities and address their needs.
Rami Fayed general manager of AbbVie in Saudi Arabia explains: 'Making a remarkable impact on people's lives is in the heart of what we do at AbbVie. Supporting the activities of the World Disability Day is part of our global CSR program 'Week of Possibilities' where we take part in various social activities and engage our team with volunteering opportunities that positively impact people's lives'.
Zuhair A. Maimini director of the King Abdullah bin Abdul Aziz Center in Jeddah commented: 'We are working hard to spread awareness about the potential of the disabled children while helping them reach their potential and identify their role in the community.'
He said AbbVie has set a good example with their swift response to participate in this event and support us with volunteers.
The activities of the World Disability Day organized by the Disabled Children's Association were full of fun and excitement while focusing on the educational side as well.
With a rich 125-year heritage of developing pharmaceuticals AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader.
A global enterprise that serves patients in 170 countries AbbVie launches in the Kingdom of Saudi Arabia with a strong commitment to the country's health care where it has been operating as Abbott for around 55 years.
AbbVie provides a broad portfolio of market leading medicines for the treatment of some of the world's most complex and serious diseases.
The portfolio includes the world's number one biologic and as well as other leading therapies in Neonatology Anesthesia Rheumatology Gastroenterology Dermatology Neurology Virology oncology and nephrology.
AbbVie's long-term growth will be fueled by a compelling pipeline with more than 10 compounds in late stage clinical trials or registration-as well as new discoveries to address diseases including Hepatitis C Alzheimer's disease Parkinson's disease multiple myeloma and endometriosis.
The event included a number of activities and programs for children under the theme of 'Sustainable Development the promise of technology.'
It was held with the support of Prince Sultan bin Naser bin Abdulaziz.
AbbVie's support for such programs aims to highlight the strong potential of the children with disabilities and address their needs.
Rami Fayed general manager of AbbVie in Saudi Arabia explains: 'Making a remarkable impact on people's lives is in the heart of what we do at AbbVie. Supporting the activities of the World Disability Day is part of our global CSR program 'Week of Possibilities' where we take part in various social activities and engage our team with volunteering opportunities that positively impact people's lives'.
Zuhair A. Maimini director of the King Abdullah bin Abdul Aziz Center in Jeddah commented: 'We are working hard to spread awareness about the potential of the disabled children while helping them reach their potential and identify their role in the community.'
He said AbbVie has set a good example with their swift response to participate in this event and support us with volunteers.
The activities of the World Disability Day organized by the Disabled Children's Association were full of fun and excitement while focusing on the educational side as well.
With a rich 125-year heritage of developing pharmaceuticals AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader.
A global enterprise that serves patients in 170 countries AbbVie launches in the Kingdom of Saudi Arabia with a strong commitment to the country's health care where it has been operating as Abbott for around 55 years.
AbbVie provides a broad portfolio of market leading medicines for the treatment of some of the world's most complex and serious diseases.
The portfolio includes the world's number one biologic and as well as other leading therapies in Neonatology Anesthesia Rheumatology Gastroenterology Dermatology Neurology Virology oncology and nephrology.
AbbVie's long-term growth will be fueled by a compelling pipeline with more than 10 compounds in late stage clinical trials or registration-as well as new discoveries to address diseases including Hepatitis C Alzheimer's disease Parkinson's disease multiple myeloma and endometriosis.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment